Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients

In North America, the number of new cases of prostate cancer increases every year. Many efforts have been made to develop more efficient and safer curative treatments for high risk prostate cancer patients. This phase III clinical trial is designed to compare the safety of a standard pelvic external beam radiation therapy (EBRT) combined with a high dose rate brachytherapy (HDRB) boost (direct insertion of radiation source over a period of minutes via flexible needles temporarily inserted in the prostate) to a shorter course of hypofractionated dose escalation radiotherapy (larger radiation dose per daily treatment) in patients with high risk prostate cancer. The investigators plan to recruit 296 patients across Quebec who will be randomized in either treatment plan.

NCT Number	NCT02303327
Lead Sponsor	Sir Mortimer B. Davis - Jewish General Hospital
Conditions	Prostate Cancer
Enrollment	307 participants
Start Date	2015-01
Primary Completion	2028-12 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-23